Ten-year literature review of global endometrial ablation with the NovaSure® device

Figures & data

Table 1 Single-arm prospective trials: amenorrhea rates after treatment with the NovaSure® endometrial ablation device (Hologic, Inc, Bedford, MA, USA)

Reference	n	Baseline age (years)	Follow-up time period (months)	Amenorrhea rate (%)
Busund et al;^Citation16 Gallinat and Nugent;^Citation20 Kalkat and Cartmill^Citation5	46–106	41.0–43.8	6	46.2–64.0
Baskett et al;^Citation15 Busund et al;^Citation16 Gallinat and Nugent^Citation20	45–146	41.0–45.0	12	40.0–58.6
Asgari et al^Citation14	20	41.7	24	30.0
Gallinat^Citation18	107	42.2	36	65.0
Gallinat^Citation19	103	42.2	60	75.0

Table 2 Single-arm prospective trials: surgical reinterventions after treatment with the NovaSure® endometrial ablation device (Hologic, Inc, Bedford, MA, USA)

Reference	n	Baseline age (years)	Follow-up time period (months)	Reintervention type (n)	Indication for reintervention (n)
Kalkat and Cartmill^Citation5	50	43.8	6	Hysterectomy (1)	Menorrhagia (1)
Busund et al^Citation16	45	41.0	12	Hysterectomy (2)	Continuous bleeding (2)
Gallinat^Citation19	107	42.2	60	Hysterectomy (3) Re-ablation (1)	Hematometra (1) Menometrorrhagia (1) Menorrhagia (1) Myoma (1)
Baskett^Citation15	146	42	12–48	Hysterectomy (10) Re-ablation (2)	Menorrhagia (10) Dysmenorrhea (2)

Figure 1 Randomized controlled trials: amenorrhea rates at 12 months.

Notes: *Statistically significant differences between groups; **amenorrhea rates for the NovaSure endometrial ablation device (Hologic, Inc, Bedford, MA, USA) were 43% for all patients (Group A) and 56% for patients treated after an equipment failure was noted (Group B). Amenorrhea rates were 8% for both Group A and B for patients treated with thermal balloon.

Figure 2 Randomized controlled trials: hysterectomy rates at 12 months.

Notes: *Hysterectomy rates for the NovaSure endometrial ablation device (Hologic, Inc, Bedford, MA, USA) were 4.8% for all patients and 3.6% for patients treated after an equipment failure was noted. Hysterectomy rate for all patients treated with thermal balloon was 9.3%. Hysterectomy rates were not reported for the subset of thermal balloon patients treated after the NovaSure equipment failure was noted.

Figure 3 Randomized controlled trials: patient satisfaction at 12 months.

Notes: *Statistically significant differences between groups; **patient satisfaction was 90% for all patients treated with the NovaSure endometrial ablation device (Hologic, Inc, Bedford, MA, USA) and 81% for all patients treated with thermal balloon. For the subset of patients treated after an equipment failure was noted in the NovaSure controller, patient satisfaction was 94% for NovaSure patients and 77% for thermal balloon patients (P=0.003).

BusundBErnoLEGrønmarkAIstreOEndometrial ablation with NovaSure GEA, a pilot studyActa Obstet Gynecol Scand2003821656812580843

 PubMed Web of Science ®Google Scholar

GallinatANugentWNovaSure impedance-controlled system for endometrial ablationJ Am Assoc Gynecol Laparosc20029328328912101323

 PubMedGoogle Scholar

KalkatRKCartmillRSNovaSure endometrial ablation under local anaesthesia in an outpatient setting: an observational studyJ Obstet Gynaecol201131215215521281033

 PubMedGoogle Scholar

BaskettTFCloughHScottTANovaSure bipolar radiofrequency endometrial ablation: report of 200 casesJ Obstet Gynaecol Can200527547347616100642

 PubMedGoogle Scholar

AsgariZMoiniASamieeHTehranianAMozafar-JalaliSSabetSEndometrial ablation with the NovaSure system in IranInt J Gynaecol Obstet20111141737521507403

 PubMed Web of Science ®Google Scholar

GallinatANovaSure impedance-controlled system for endometrial ablation: three-year follow-up on 107 patientsAm J Obstet Gynecol200419151585158915547528

 PubMed Web of Science ®Google Scholar

GallinatAAn impedance-controlled system for endometrial ablation: five-year follow-up of 107 patientsJ Reprod Med200752646747217694962

 PubMed Web of Science ®Google Scholar